| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 9,605 | 10,394 | ||
| General and administrative | 5,867 | 6,703 | ||
| Total operating expenses | 15,472 | 17,097 | ||
| Interest income | 1,903 | 2,080 | ||
| Other expense | 5 | 16 | ||
| Total other income | 1,898 | 2,064 | ||
| Net loss | -13,574 | -15,033 | ||
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -0.11 | -0.12 | ||
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.11 | -0.12 | ||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares) | 126,305,122 | 126,204,632 | ||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares) | 126,305,122 | 126,204,632 | ||
Nautilus Biotechnology, Inc. (NAUT)
Nautilus Biotechnology, Inc. (NAUT)